$21.160
-0.110 (-0.52%)At close
SI News
SI Events
Shoulder Innovations Appoints Jon Osborne as Chief Commercial Officer
Shoulder Innovations announced the promotion of Jon Osborne to Chief Commercial Officer, effective August 6. Osborne, who most recently served as VP of Commercial Development, will now have responsibility for all elements of Shoulder Innovations' commercial organization. Prior to joining Shoulder Innovations as VP of Commercial Development in September 2023, Osborne held several positions of increasing responsibility from 2014 to 2023 at Smith & Nephew, most recently as VP of Commercial Marketing for the Sports Medicine business in the Americas. Earlier in his career at Smith & Nephew, he also served as an Area Vice President of Sales and as Director of Global Marketing, where he launched products and built distribution across six continents. Prior to Smith & Nephew, Osborne worked in sales management, global marketing, and general management from 1998 to 2014 in both domestic and international markets at ArthroCare Corporation, Tornier USA, and Team Surgical.
Shoulder Innovations Files $300M Mixed Securities Shelf
Shoulder Innovations files $300M mixed securities shelf
Shoulder Innovations Q2 Revenue $17.2M Beats Expectations
Reports Q2 revenue $17.2M, consensus $16.57M. "Our Q2 results build on a strong start to the year and reflect remarkable momentum across every dimension of our business," said Rob Ball, CEO. "We continued to rapidly onboard new surgeons against a large, underpenetrated market opportunity, deepened utilization within our existing surgeon base, and advanced a broad and increasingly differentiated product pipeline. This performance resulted in net revenue growth of 56% and implant volume growth of approximately 50%, enabling us to increase our outlook for the full year. Our confidence in what lies ahead has never been stronger. The commercial organization we've built continues to perform, our innovation pipeline is growing, and our conviction in the team's ability to execute is high. With a strengthened financial foundation following our recent debt refinancing, we believe Shoulder Innovations remains in the early stages of what we can accomplish in transforming shoulder surgical care, and we look forward to demonstrating that in the back half of 2026 and beyond."
Shoulder Innovations Q1 Revenue $16.71M Beats Expectations
Reports Q1 revenue $16.71M, consensus $14.53M. "We are very pleased with our first quarter performance, which reflects accelerating revenue growth and intensifying commercial momentum across our entire organization," said Rob Ball, CEO of Shoulder Innovations. "Net revenue growth of 65%, implant volume growth of 51%, and continued improvement in gross margin demonstrate the strength and efficiency of our rapidly expanding ecosystem." Ball continued, "Building on this traction, recent product portfolio milestones, including the full commercial launch of our InSet I-135RFX Humeral Stem, meaningfully extend the comprehensive suite of solutions we offer surgeons and their patients. This disciplined financial and operational execution to start the year provides us with increased confidence in the trajectory of the business and enables us to increase our full year 2026 revenue guidance."
Shoulder Innovations FY26 Revenue View Growth of 31%-37%
FY26 revenue view represents a growth of 31%-37% vs. FY25. Rob Ball, CEO of Shoulder Innovations said, "Looking into 2026, our momentum remains strong. Our key strategic priorities are focused on delivering sustained growth through world class execution and innovation. With a growing product portfolio, a comprehensive enabling technology strategy, our expanding commercial talent, and a strong balance sheet, we believe we are well positioned to further extend and strengthen our leadership position in shoulder surgical care in the years ahead."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.